Mesoblast (MESO) to Release Quarterly Earnings on Thursday

Mesoblast (NASDAQ:MESO) is anticipated to announce its earnings results on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $2.39 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Mesoblast Stock Performance

NASDAQ MESO opened at $16.23 on Tuesday. The stock’s fifty day moving average is $17.91 and its two-hundred day moving average is $11.91. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. Mesoblast has a fifty-two week low of $1.91 and a fifty-two week high of $22.00.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on MESO shares. Cantor Fitzgerald raised Mesoblast to a “strong-buy” rating in a research note on Thursday, January 30th. Piper Sandler reissued an “overweight” rating and set a $24.00 price objective (up previously from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. Finally, Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Mesoblast has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.